PHKA2-AS1: A Potential Drug Target and Biomarker (G100132163)

Target Name: PHKA2-AS1

NCBI ID: G100132163

Other Name(s): PHKA2 antisense RNA 1

PHKA2-AS1: A Potential Drug Target and Biomarker

PHKA2-AS1, also known as AS1-100, is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of the cytoskeleton. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of PHKA2-AS1 as a potential drug target and biomarker comes from a study by the research group led by Dr. Xujiong Ye at the University of California, San Diego. The study, published in the journal Nature Communications, identified PHKA2-AS1 as a key regulator of the cytoskeleton and a potential drug target for neurodegenerative diseases.

PHKA2-AS1 is a protein that is composed of 256 amino acids and has a molecular weight of 31 kDa. It is located in the endoplasmic reticulum and is involved in the regulation of the cytoskeleton, which is the structure that gives shape to the cell. The cytoskeleton is responsible for the maintenance of cell shape, stability, and movement.

PHKA2-AS1 is a key regulator of the cytoskeleton because it helps to regulate the distribution of organelles in the cell. It does this by interacting with other proteins that are involved in the cytoskeleton, including the protein known as T-complex. The T-complex is a protein that is involved in the regulation of the cytoskeleton and is composed of the proteins T-type cytoskeleton protein (T-CF) and the protein known as p180.

PHKA2-AS1 is also involved in the regulation of the cytoskeleton because it helps to control the dynamics of the cytoskeleton. This is done by interacting with other proteins that are involved in the cytoskeleton, including the protein known as N-cadherin. N-cadherin is a protein that is involved in cell-cell adhesion and is composed of two subunits.

PHKA2-AS1 is a potential drug target for neurodegenerative diseases because it is involved in the regulation of the cytoskeleton and is a key regulator of the cytoskeleton. This suggests that if a drug can inhibit the activity of PHKA2-AS1, it may be effective in treating neurodegenerative diseases.

PHKA2-AS1 is also a potential biomarker for neurodegenerative diseases because it is involved in the regulation of the cytoskeleton and is a key regulator of the cytoskeleton. This suggests that if the level of PHKA2-AS1 is decreased in the brain, it may be a sign of neurodegenerative disease.

In conclusion, PHKA2-AS1 is a protein that is involved in the regulation of the cytoskeleton and has the potential to be a drug target and biomarker for various neurodegenerative diseases. Further research is needed to fully understand the role of PHKA2-AS1 in neurodegenerative diseases and to develop effective treatments.

Protein Name: PHKA2 Antisense RNA 1

More Common Targets